← Back

Pulike Biological Engineering

Pulike Biological Engineering, Inc. researches, develops, produces, and sells veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. Its offerings include vaccines, antibodies, and medicines for livestock, poultry, and pets. The company was founded in 1995 and is headquartered in Luoyang, China.

Country
Price · split & dividend adjusted
News & notes moving 603566.CG
603566.CG▲

Pulike Subsidiary Receives National Class II New Veterinary Drug Registration Certificate for Denaverine Hydrochloride Injection

Pulike announced that, following review by the Ministry of Agriculture and Rural Affairs, the Denaverine Hydrochloride Injection jointly declared by its wholly owned subsidiary Luoyang Huizhong Veterinary Medicine and other entities was approved as a new veterinary drug, and the issuance of the New Veterinary Drug Registration Certificate was publicized on September 14, 2026. The new veterinary drug is registered as Class II, with denaverine hydrochloride as the main ingredient. It is indicated for promoting soft tissue dilation of the birth canal and facilitating parturition in first-calf heifers, administered as a single intramuscular injection of 10 milliliters, used only once. The company stated that this product is a national Class II new veterinary drug.
603566.CG ▲
Jiemian·5dRead more →
603566.CG▼

Pulike's 2026 interim net profit falls 33.45% year on year

Pulike released its 2026 interim report, with net profit attributable to the parent company of 77.32 million yuan, down 33.45% from the same period last year. Total operating revenue was 491 million yuan, down 12.18% year on year. Net cash inflow from operating activities was 78.07 million yuan, down 59.98% year on year. The latest gross margin was 55.76%, down 4.01 percentage points from a year earlier. Diluted earnings per share were 0.23 yuan, down 32.35% year on year.
603566.CG ▼
Jiemian·25dRead more →
603566.CG▲

Pulike Subsidiary Obtains New Veterinary Drug Registration Certificate for Fluralaner and Moxidectin Spot-On Solution

Pulike's wholly owned subsidiary Luoyang Huizhong Veterinary Medicine Co., Ltd., together with other organizations, has received approval from the Ministry of Agriculture and Rural Affairs for the Fluralaner and Moxidectin Spot-On Solution as a new veterinary drug, along with a New Veterinary Drug Registration Certificate. The product is a Class II new veterinary drug used to treat flea and intestinal roundworm infections in cats, providing up to 12 weeks of protection. The company stated that obtaining this certificate reflects its emphasis on technological innovation and increased R&D investment, and will play a positive role in enhancing product competitiveness and driving growth in its pet business segment.
603566.CG ▲
CLS·26dRead more →
© 2026 MarketDXAsset